XML 16 R9.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Fair Value Measurements and Marketable Securities | 3 Months Ended
--- | ---
Mar. 31, 2024
Fair Value Disclosures [Abstract] |
Fair Value Measurements and Marketable Securities | 3. Fair Value Measurements and Marketable Securities Fair Value Measurements The Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, "Fair Value Measurements and Disclosures", which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:
Level – 1 | Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level – 2 | Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
Level – 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
The Company’s financial instruments consist primarily of cash, cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of March 31, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity. The following tables summarize the Company’s cash equivalents and marketable securities as of March 31, 2024 and December 31, 2023:
|  | Total |  |  | Quoted Prices in Active Markets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
|  | (in thousands) |
March 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |
Money market funds invested in government securities |  | $ | 69,905 |  |  | $ | 69,905 |  |  | $ | — |  |  | $ | — |
U.S. Treasury Bills |  |  | 39,813 |  |  |  | 39,813 |  |  |  | — |  |  |  | — |
Total cash equivalents |  |  | 109,718 |  |  |  | 109,718 |  |  |  | — |  |  |  | — |
Marketable securities: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bills |  |  | 23,058 |  |  |  | 23,058 |  |  |  | — |  |  |  | — |
U.S. Government securities |  |  | 79,835 |  |  |  | — |  |  |  | 79,835 |  |  |  | — |
Corporate bonds |  |  | 25,989 |  |  |  | — |  |  |  | 25,989 |  |  |  | — |
Total marketable securities |  |  | 128,882 |  |  |  | 23,058 |  |  |  | 105,824 |  |  |  | — |
Total cash equivalents and marketable securities |  | $ | 238,600 |  |  | $ | 132,776 |  |  | $ | 105,824 |  |  | $ | — |
December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents: |  |  |  |  |  |  |  |  |  |  |  |
Money market funds invested in government securities |  | $ | 24,701 |  |  | $ | 24,701 |  |  | $ | — |  |  | $ | — |
Total cash equivalents |  |  | 24,701 |  |  |  | 24,701 |  |  |  | — |  |  |  | — |
Marketable securities: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bills |  |  | 17,334 |  |  |  | 17,334 |  |  |  | — |  |  |  | — |
U.S. Government securities |  |  | 35,719 |  |  |  | — |  |  |  | 35,719 |  |  |  | — |
Corporate bonds |  |  | 6,988 |  |  |  | — |  |  |  | 6,988 |  |  |  | — |
Total marketable securities |  |  | 60,041 |  |  |  | 17,334 |  |  |  | 42,707 |  |  |  | — |
Total cash equivalents and marketable securities |  | $ | 84,742 |  |  | $ | 42,035 |  |  | $ | 42,707 |  |  | $ | — |
The accrued interest receivable related to the Company’s investments was $1.1 million and $0.3 million as of March 31, 2024 and December 31, 2023, respectively, and is included in prepaid expenses and other current assets on the condensed consolidated balance sheet. The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. As of March 31, 2024 and December 31, 2023, the unrealized losses for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of March 31, 2024 and December 31, 2023, no allowances for credit losses for the Company’s investments were recorded. During the three months ended March 31, 2024 and 2023, the Company did no t recognize any impairment losses related to investments. Marketable securities The following table summarizes the Company's marketable securities as of March 31, 2024 and December 31, 2023.
|  | Amortized Cost |  |  | Gross Unrealized Gains |  |  | Gross Unrealized Losses |  |  | Fair Value |
|  | (in thousands) |
March 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bills |  | $ | 23,061 |  |  | $ | — |  |  | $ | (3 | ) |  | $ | 23,058 |
U.S. Government securities |  |  | 79,849 |  |  |  | 6 |  |  |  | (20 | ) |  |  | 79,835 |
Corporate bonds |  |  | 25,997 |  |  |  | 3 |  |  |  | (11 | ) |  |  | 25,989 |
Total marketable securities |  | $ | 128,907 |  |  | $ | 9 |  |  | $ | (34 | ) |  | $ | 128,882 |
December 31, 2023 |  |  |  |  |  |  |  |  |  |  |  |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury Bills |  | $ | 17,330 |  |  | $ | 4 |  |  | $ | — |  |  | $ | 17,334 |
U.S. Government securities |  |  | 35,653 |  |  |  | 66 |  |  |  | — |  |  |  | 35,719 |
Corporate bonds |  |  | 6,977 |  |  |  | 11 |  |  |  | — |  |  |  | 6,988 |
Total marketable securities |  | $ | 59,960 |  |  | $ | 81 |  |  | $ | — |  |  | $ | 60,041 |
No marketable securities held as of March 31, 2024 or December 31, 2023, had remaining maturities greater than two years. As of March 31, 2024 and December 31, 2023, the Company held no investments that have been in a continuous loss position for 12 months or longer.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration